Bayer could become the latest casualty of Roche’s targeted pricing
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Pfizer shoots for a high price with tafamidis
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
Peanut therapy makers face pricing pushback
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
Rebate ban would not necessarily equal savings, Icer says
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Big pharma execs decry rebates, but how big might list price cuts be?
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Regeneron and Sanofi play follow the leader on Praluent pricing
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
No price relief in 2019, Pfizer confirms
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
Brilinta could finally get a chance to shine
A value-based deal would boost prices should Astrazeneca's struggling heart-disease pill Brilinta outperform outcomes benchmarks.
